Eyal Dor-On

Biochemistry, Genetics and Molecular Biology · Life Sciences

6h-index194citations50works0.72yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Research and Treatments(13), Glioma Diagnosis and Treatment(5), Autophagy in Disease and Therapy(5), Cancer, Hypoxia, and Metabolism(5), PARP inhibition in cancer therapy(5)

Publications50 total

PP01.13: Efficacy of Tumor Treating Fields (TTFields) Together With Standard Chemotherapy and PD-1 Blockage in Preclinical Models of Small Cell Lung Carcinoma
Journal of Thoracic Oncology·2026
Abstract B035: Tumor Treating Fields (TTFields) together with FOLFIRINOX are effective for the treatment of pancreatic cancer, in vitro and in vivo
Cancer Research·2025
The transcriptomic fingerprint of cancer response to Tumor Treating Fields (TTFields)
Cell Death Discovery·2025· 2 citedOpen Access
Abstract 1691: Tumor treating fields (TTFields) sensitize BRCA wild type pancreatic cancer cells to treatment with FOLFIRINOX
Cancer Research·2025
Abstract 4195: Efficacy of tumor treating fields (TTFields) applied with cisplatin and paclitaxel in cervical cancer cells
Cancer Research·2025
Abstract 5668: Preclinical efficacy of tumor treating fields (TTFields) for small cell lung carcinoma (SCLC)
Cancer Research·2025· 1 cited
341P: Efficacy of tumor treating fields (TTFields) in preclinical models of small cell lung carcinoma (SCLC)
Journal of Thoracic Oncology·2025Open Access
Effects of tumor treating fields (TTFields) with FOLFIRINOX on BRCA WT pancreatic cancer cells.
Journal of Clinical Oncology·2025· 1 cited
EP.03F.04 Treatment of Non-Small Cell Lung Carcinoma (NSCLC) Cells with Tumor Treating Fields (TTFields) And DNA-Dependent Protein Kinase (PK) Inhibitors
Journal of Thoracic Oncology·2024Open Access
Tumor Treating Fields (TTFields) induce homologous recombination deficiency in ovarian cancer cells, thus mitigating drug resistance
Frontiers in Oncology·2024· 7 citedOpen Access
A novel chemical entity, that reverses Warburg metabolism by disrupting VDAC1/HK2 interaction through “Toposteric Effect” in Cancer
Research Square (Research Square)·2024· 1 citedOpen Access
Abstract 7135: Preclinical effects of Tumor Treating Fields (TTFields) with PARP inhibitors in ovarian cancer
Cancer Research·2024
Abstract 7219: Preclinical investigations of concomitant tumor treating fields (TTFields) with cisplatin for treatment of cervical cancer
Cancer Research·2024
Abstract 7134: Treatment of pancreatic cancer cells with tumor treating fields (TTFields) and PARP inhibitors
Cancer Research·2024
Abstract B071: Tumor Treating Fields (TTFields) together with PARP inhibitors for treatment of pancreatic cancer cells
Cancer Research·2024
Abstract B027: Preclinical efficacy of Tumor Treating Fields (TTFields) applied with PARP inhibitors or carboplatin in ovarian cancer
Cancer Research·2024
Abstract B028: Preclinical effects of Tumor Treating Fields (TTFields) applied with cisplatin for treatment of cervical cancer
Cancer Research·2024
Tumor Treating Fields (TTFields) demonstrate antiviral functions in vitro, and safety for application to COVID-19 patients in a pilot clinical study
Frontiers in Microbiology·2023Open Access
EP02.02-02 Transcriptomic Response to Tumor Treating Fields (TTFields) Across Tumor Types
Journal of Thoracic Oncology·2023Open Access
P-99 Tumor treating fields (TTFields) are effective for treatment of gastric cancer cells, boosting the activity of FOLFOX
Annals of Oncology·2023Open Access
page 1 of 3Next →

Frequent Co-authors

Moshe Giladi(42), Adi Haber(41), Yoram Palti(40), Uri Weinberg(29), Antonia Martinez-Conde(17), Einav Zeevi(17), Shiri Davidi(14), Roni Frechtel-Gerzi(13), Hila Fishman(13), Tali Voloshin(12), Yaara Porat(11), Anna Shteingauz(11), Yelena Mumblat(10), Rosa S. Schneiderman(9), Catherine Tempel-Brami(9), Adrian Kinzel(9), Roni Monin(9), Hila Ene(9), Itai Tzchori(9), Roni Blatt(8)